KRAS mutant colorectal tumors: Past and present

Small GTPases

Volumn 3, Issue 1, 2012, Pages

  Brand, Toni M ^a   Wheeler, Deric L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cetuximab; EGFR; GTPase; KRAS; Metastatic colorectal cancer; Resistance

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AZ D6244; B RAF KINASE INHIBITOR; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GUANOSINE TRIPHOSPHATASE; HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MONOCLONAL ANTIBODY; PANITUMUMAB; PIMASERTIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG; VEMURAFENIB;

CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL TUMOR; DRUG ACTIVITY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; METASTASIS; METASTATIC COLORECTAL TUMOR; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

EID: 84859098993     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.3.1.18751     Document Type: Review

References (47)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300. PMID: 20610543; http://dx.doi.org/10.3322/caac.20073
2. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103:1765-1772. PMID:21139621; http://dx.doi.org/10.1038/sj.bjc.6606008
3. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505-516. PMID:16829981; http://dx.doi.org/10.1038/nrm1962
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2:127-137. PMID:11252954; http://dx.doi.org/10.1038/35052073
5. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl 4):S9-S15. PMID:11597399; http://dx.doi.org/10.1016/S0959-8049(01)00231-3
6. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-311. PMID:15837620; http://dx.doi.org/10.1016/j.ccr.2005.03.003
7. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98:1275-1280. PMID:17498200; http://dx.doi.org/10.1111/j.1349-7006.2007.00510.x
8. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13:1552-1561. PMID:17332301; http://dx.doi.org/10.1158/1078-0432.CCR-06-1726
9. Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov 2006; 5:987-988. PMID:17201026; http://dx.doi.org/10.1038/nrd2204
10. Yang XD, Jia XC, Corvalan JRF, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23. PMID:11255078; http://dx.doi.org/10.1016/S1040-8428(00)00134-7
11. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345. PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025
12. van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417. PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
13. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008; 19:1288-1292. PMID:18349029
14. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810. PMID:15677699; http://dx.doi.org/10.1200/JCO.2005.08.037
15. Normanno N, Tejpar S, Morgillo F, De Luca A, van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6:519-527. PMID:19636327; http://dx.doi.org/10.1038/nrclinonc.2009.111
16. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308. PMID:17384584; http://dx.doi.org/10.1038/nrc2109
17. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366:643-654. PMID: 8259209; http://dx.doi.org/10.1038/366643a0
18. Matsubara K, Kishida S, Matsuura Y, Kitayama H, Noda M, Kikuchi A. Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation. Oncogene 1999; 18:1303-1312. PMID:10022812; http://dx.doi.org/10.1038/sj.onc.1202425
19. Bos JL, Fearon ER, Hamilton SR, Verlaandevries M, Vanboom JH, Vandereb AJ, et al. Prevalence of Ras Gene-Mutations in Human Colorectal Cancers. Nature 1987; 327:293-297. PMID:3587348; http://dx.doi.org/10.1038/327293a0
20. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000; 60:6750-6756. PMID:11118062
21. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. ASCO Annual Meeting. Chicago, Illinois, 2011.
22. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-648. PMID:17363584; http://dx.doi.org/10.1158/0008-5472.CAN-06-4158
23. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096. PMID:19188670; http://dx.doi.org/10.1200/JCO.2009.21.9170
24. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4: 677-685. PMID:15827342; http://dx.doi.org/10.1158/1535-7163.MCT-04-0297
25. Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, et al. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev 2010; 36:S1-S5. PMID:21129603; http://dx.doi.org/10.1016/S0305-7372(10)70012-8
26. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27:15s((suppl; abstr 9000))
27. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596-599. PMID:20823850; http://dx.doi.org/10.1038/nature09454
28. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431-435. PMID: 20130576; http://dx.doi.org/10.1038/nature08833
29. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-362. PMID: 16273091; http://dx.doi.org/10.1038/nature04304
30. Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011;71:445-453. PMID:21118963; http://dx.doi.org/10.1158/0008-5472.CAN-10-3058
31. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810-816. PMID:10395327; http://dx.doi.org/10.1038/10533
32. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003; 30:105-116. PMID:14613031; http://dx.doi.org/10.1053/j.seminoncol.2003.08.012
33. Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-4462. PMID:15483017; http://dx.doi.org/10.1200/JCO.2004.01.185
34. Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 29:1021-1028.PMID:20127139; http://dx.doi.org/10.1007/s10637-010-9392-8
35. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011; 4:17. PMID:21447798; http://dx.doi.org/10.1126/scisignal.2001752
36. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63:5656-5668. PMID:14522880
37. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, et al. Evaluation of farnesyl: protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001; 61:8758-8768. PMID:11751396
38. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30:1128-1133. PMID:10534157; http://dx.doi.org/10.1016/S0046-8177(99)90027-8
39. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, et al. C-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003; 9:1480-1488. PMID:12684423
40. Eng C, Van Cutsem E, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell P, et al A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wildtype (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analysesASCO Annual Meeting. Chicago, Illinois, 2011.
41. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, et al. Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. J Clin Oncol 2010; 28:4240-4246. PMID:20713879; http://dx.doi.org/10.1200/JCO.2010.30.4154
42. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10:709-717. PMID:19573800; http://dx.doi.org/10.1016/S1470-2045(09)70137-8
43. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation. Clin Cancer Res 2011; 17:472-482. PMID:21098338; http://dx.doi.org/10.1158/1078-0432.CCR-10-0568
44. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008; 68:8322-8332. PMID: 18922904; http://dx.doi.org/10.1158/0008-5472.CAN-07-6720
45. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clin Colorectal Cancer 2010; 9:89-94. PMID:20378502; http://dx.doi.org/10.3816/CCC.2010.n.012
46. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 2011; 30:561-574. PMID:20956938; http://dx.doi.org/10.1038/onc.2010.430
47. de Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy- refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-1820. PMID: 20978259; http://dx.doi.org/10.1001/jama.2010.1535